Conversely, a Korean article, which also demonstrated the independent prognostic value of PBRM1 expression, suggested that the negative prognostic impact of PBRM1 LOF was limited to lower-stage tumors (stage I/II; p = 0.001 for cancer specific survival (CSS)/PFS) and not to higher-stage tumors (stage III/IV; p > 0.05), although most of the patients (≈76.6%) were stage I/II [45]. Here, PBRM1 is linked to cancer.